Dfe Pharma
Dfe Pharma, headquartered in Germany, is a leading provider of excipients and pharmaceutical solutions, specialising in the development and manufacturing of high-quality products for the global pharmaceutical industry. Founded in 2015, the company has quickly established itself as a key player in the market, with a strong presence in Europe, North America, and Asia. Dfe Pharma's core offerings include a diverse range of excipients, such as binders, fillers, and disintegrants, which are essential for the formulation of solid dosage forms. What sets Dfe Pharma apart is its commitment to innovation and quality, ensuring that their products meet the stringent requirements of the pharmaceutical sector. With a focus on customer collaboration and tailored solutions, Dfe Pharma continues to enhance its market position, contributing to the success of its partners in the ever-evolving pharmaceutical landscape.
DitchCarbon Score
How does Dfe Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dfe Pharma's score of 42 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dfe Pharma's reported carbon emissions
In 2024, DFE Pharma reported total Scope 3 emissions of approximately 815,000,000 kg CO2e. This marks a decrease from 2023, where emissions were about 917,000,000 kg CO2e, and from 2022, which recorded approximately 931,000,000 kg CO2e. The company has not disclosed any Scope 1 or Scope 2 emissions data for these years. DFE Pharma has set ambitious climate commitments, aiming for 100% carbon neutrality for Scope 1 and Scope 2 emissions by 2030. Additionally, the company has committed to reducing absolute Scope 1 and 2 greenhouse gas emissions by 42% from a 2021 baseline by 2030. For Scope 3 emissions, DFE Pharma targets a reduction of 25% from purchased goods and services, upstream transportation and distribution, and end-of-life treatment of sold products within the same timeframe. Furthermore, they aim to reduce absolute Scope 3 FLAG emissions by 30.3% by 2030 and have pledged to achieve no deforestation across primary deforestation-linked commodities by December 31, 2025. It is important to note that DFE Pharma's emissions data and targets are cascaded from its parent company, DMV-Fonterra Excipients GmbH & Co. KG, reflecting a corporate family relationship. This alignment with broader corporate sustainability goals underscores DFE Pharma's commitment to addressing climate change within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 6,566,000 | - | - | - | - |
| Scope 2 | 7,916,000 | - | - | - | - |
| Scope 3 | 989,802,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dfe Pharma is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
